Biohaven Announces Progress Across Its Graves' Disease Program
Biohaven is advancing its Graves' disease treatment candidate, BHV-1300, with ongoing Phase 3 clinical trials and the presentation of new scientific data.
Stocks · News reference
Deutsche Bank Adjusts Biohaven Price Target to $23 From $26, Maintains Buy Rating
Deutsche Bank has revised its 12-month price target for Biohaven Ltd. to $23 from the previous $26, while maintaining a Buy rating on the stock.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Biohaven at Overweight, Raises Price Target to $21
Morgan Stanley has reaffirmed its 'Overweight' rating on Biohaven (BHVN) and increased its price target for the company's shares from $19 to $21.
Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32
Biohaven Ltd. Analyst Price Target Adjusted to $25
Analysts have updated the 12-month price target for Biohaven Ltd. to $25, reflecting a slight decrease from the previous average of $25.17.
Biohaven Reports Q3 2026 Financial Results and Regulatory Updates
Biohaven announced its third-quarter 2026 financial results, including an adjusted loss of $0.73 per share, and provided updates on its clinical pipeline and regulatory progress.
Biohaven Presents Data on BHV-1420 at ASN Kidney Week 2026
Biohaven Ltd. showcased its investigational TRAP extracellular protein degrader, BHV-1420, in an oral presentation at the ASN Kidney Week 2026 conference.